DoW Toxic Exposures Investigator Initiated Research Award

The DoW Toxic Exposures Investigator Initiated Research Award is a forecasted federal research funding opportunity administered by the U.S. Department of Defense through the Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA). The funding opportunity is part of the fiscal year Toxic Exposures Research Program and is intended to support scientific and medical research focused on diseases and conditions associated with military-related toxic exposures. The opportunity is listed on Grants.gov as a discretionary grant under Assistance Listing 12.420, Military Medical Research and Development. The program seeks to encourage innovative investigator-initiated projects that can improve understanding, treatment, and patient care outcomes for individuals affected by toxic exposure conditions connected to military service. The program is designed to support a broad spectrum of biomedical and translational research activities. Eligible projects may include basic laboratory research, translational studies, preclinical work involving animal models, research involving human subjects, and correlative studies linked to existing clinical trials. The funding announcement specifically notes that New Approach Methodologies may also be used, signaling interest in modernized and potentially nontraditional research approaches. The funding scope indicates that the agency is seeking projects capable of making important contributions to scientific understanding and clinical care related to toxic exposures experienced in military environments. The opportunity is forecasted with an estimated total program funding amount of $2,400,000 and an anticipated three awards. No award ceiling or award floor amounts are currently specified in the forecast notice. The funding instrument type is listed as a grant, and no cost sharing or matching requirement is required for applicants. Because this is a forecasted opportunity, applicants should anticipate additional details to become available when the full solicitation package is officially released. The estimated award date and project start date are both listed as September 30, 2027, indicating that projects are expected to begin at the end of fiscal year 2027 following review and selection processes. Eligibility is currently described as unrestricted, meaning the opportunity is open to any type of entity, subject to any future clarifications provided in the official solicitation materials. The notice does not currently limit eligibility by geography, organization type, or institution category. Based on the unrestricted eligibility statement and the federal nature of the opportunity, applicants may include institutions of higher education, nonprofit organizations, private research institutions, government entities, small businesses, and potentially other research-capable entities. Additional eligibility clarifications may be included in the final funding announcement once officially posted. The application process has not yet formally opened. The forecast indicates an estimated posting date of July 8, 2026, with an estimated application due date of November 19, 2026. No pre-application requirements such as letters of intent, concept papers, or pre-proposals are identified in the forecast notice. Similarly, no specific application components, evaluation criteria, or submission system requirements are yet detailed beyond the reference to the eBRAP Help Desk, which suggests that the Electronic Biomedical Research Application Portal may be involved in the submission or administration process. Applicants should monitor both Grants.gov and the Congressionally Directed Medical Research Programs website for release of the complete funding opportunity announcement and application instructions. The funding opportunity appears to be part of an annually recurring federal research program tied to the Toxic Exposures Research Program. The associated press release and naming convention indicate a fiscal year-based program structure that is likely reissued in future cycles. The opportunity is currently in forecast status because the application opening date is in the future relative to the analysis date. Interested applicants are encouraged to begin preparing research concepts, collaborations, and institutional approvals in advance of the estimated opening date. Questions related to the opportunity may currently be directed to the eBRAP Help Desk at 301-682-5507, which is the only contact information presently provided in the forecast notice.

Focus proposals on diseases or conditions associated with military-related toxic exposures and demonstrate potential contributions to research advancement or patient care outcomes.